J
John Greene
Researcher at Trinity College, Dublin
Publications - 23
Citations - 657
John Greene is an academic researcher from Trinity College, Dublin. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 5, co-authored 21 publications receiving 439 citations. Previous affiliations of John Greene include Cork University Hospital & University Hospital Waterford.
Papers
More filters
Journal ArticleDOI
Circular RNAs: Biogenesis, Function and Role in Human Diseases.
John Greene,John Greene,Anne-Marie Baird,Lauren Brady,Marvin Lim,Steven G. Gray,Raymond S. McDermott,Stephen P. Finn +7 more
TL;DR: It has been proposed that circRNA regulate gene expression at the transcriptional or post-transcriptional level by interacting with miRNAs and that circRNAs may have a role in regulating miRNA function in cancer initiation and progression.
Journal ArticleDOI
Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide.
John Greene,Anne-Marie Baird,Orla Casey,Lauren Brady,Gordon Blackshields,Marvin Lim,Marvin Lim,Odharnaith O'Brien,Steven G. Gray,Raymond S. McDermott,Raymond S. McDermott,Stephen P. Finn +11 more
TL;DR: This is one of the first studies to profile and demonstrate discrete circRNAs expression patterns in an enzalutamide resistant cell line model of prostate cancer, and suggests that hsa_circ_0004870, through RBM39, may play a critical role in the development of enzyme resistance in CRPC.
Journal ArticleDOI
The role of anthracyclines in the treatment of early breast cancer
John Greene,Bryan T. Hennessy +1 more
TL;DR: The use of taxanes in early breast cancer has overtaken the use of anthracyclines, particularly in women with HER2–positive breast cancer, and Ongoing trials will determine whether taxane-based chemotherapy has equivalent efficacy to anthRacycline-based regimens in adjuvant therapy of HER2-negative early Breast cancer.
Journal ArticleDOI
Secreted factors from metastatic prostate cancer cells stimulate mesenchymal stem cell transition to a pro-tumourigenic 'activated' state that enhances prostate cancer cell migration
Sarah M. Ridge,Dibyangana D. Bhattacharyya,Eoin Dervan,Serika D. Naicker,Amy J. Burke,J.M. Murphy,Karen O’Leary,John Greene,Aideen E. Ryan,Francis J. Sullivan,Sharon A. Glynn +10 more
TL;DR: MSCs developed an altered phenotype in response to prostate cancer conditioned medium which resulted in increased secretion of pro‐inflammatory cytokines, modified functional activity and the chemoattraction of prostate cancer cells.
Journal ArticleDOI
RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies
Marvin Lim,Anne-Marie Baird,Anne-Marie Baird,John Aird,John Greene,Dhruv Kapoor,Steven G. Gray,Steven G. Gray,Ray McDermott,Stephen P. Finn +9 more
TL;DR: This review focuses on the evidence for the role of RNAs in prostate cancer, and their use as diagnostic and prognostic markers, and targets for treatment in this disease.